var data={"title":"Azithromycin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Azithromycin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387712?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=azithromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Azithromycin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=azithromycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Azithromycin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983183\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zithromax;</li>\n      <li>Zithromax Tri-Pak;</li>\n      <li>Zithromax Z-Pak;</li>\n      <li>Zmax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983184\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zithromax;</li>\n      <li>Zmax SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983188\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Macrolide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983294\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Extended-release suspension (Zmax) is not interchangeable with immediate-release formulations.</b> Use should be limited to approved indications. All doses are expressed as immediate release azithromycin unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acne vulgaris (off-label use):</b> Oral: Dosing regimens used in clinical trials have varied greatly. All trials used pulse-dosing regimens; regimens included: 500 mg once daily for 4 consecutive days per month for 3 consecutive months (Babaeinejad 2011; Parsad 2001) <b>or</b> 500 mg once daily for 3 days in the first week, followed by 500 mg once weekly until week 10 (Maleszka 2011) <b>or</b> 500 mg once daily for 3 consecutive days each week in month 1, followed by 500 mg once daily for 2 consecutive days each week in month 2, then 500 mg once daily for 1 day each week in month 3 (Kus 2005). The shortest possible duration should be used to minimize development of bacterial resistance; re-evaluate at 3 to 4 months (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Babesiosis (off-label use):</b> Oral: 500 to 1,000 mg on day 1, followed by 250 mg once daily for 7 to 10 days with atovaquone; higher doses may be required in immunocompromised patients (600 to 1,000 mg daily). <b>Note:</b> Relapsing infection may require at least 6 weeks of therapy (Krause 2000; Vannier 2012; IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial sinusitis, acute:</b> Oral: 500 mg daily for a total of 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension (Zmax): 2 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchiolitis obliterans syndrome (off-label use):</b> Oral: 250 mg daily for 5 days, followed by 250 mg 3 times per week for a minimum of 3 months (Meyer 2014). <b>Note:</b> It is unclear whether azithromycin should be continued long-term if a benefit is observed or if it should be discontinued if lung function does not improve (Meyer 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cat scratch disease (off-label use):</b> Oral: &ge;45.5 kg: 500 mg as a single dose, then 250 mg once daily for 4 additional days (Bass 1998; Stevens 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cesarean section (nonelective), prophylaxis (preoperative) (off-label use): </b>IV: 500 mg as a single dose 1 hour prior to surgical incision; used in conjunction with standard preoperative antibiotics (Tita 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chancroid due to </b> <b><i>H. ducreyi:</i></b> Oral: 1 g as a single dose. <b>Note:</b> Data are limited concerning the efficacy in HIV infected patients (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Chlamydia trachomatis </b></i>\n      <b>infection:</b> Cervicitis, urethritis<b>:</b> Oral: 1 g as a single dose (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera (off-label use):</b> Oral: 1 g as a single dose (Saha 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, conjunctivitis (off-label use):</b> Oral: 1 g as a single dose in combination with ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, disseminated (arthritis, arthritis-dermatitis, meningitis, endocarditis) (off-label use): </b>Oral: 1 g as a single dose in combination with ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, expedited partner therapy (off-label use):</b> Oral: 1 g as a single dose in combination with cefixime (CDC [Workowski 2015]). <b> Note:</b> To be used only for heterosexual partners with gonorrhea if health department partner-management strategies are impractical/unavailable and there is concern by the provider for the prompt evaluation and treatment of the partner; medication may be delivered to partner by patient, collaborating pharmacy, or disease investigation specialist as permitted by law; written materials to educate partners about their exposure to gonorrhea, importance of therapy, and when to seek clinical evaluation for adverse reactions/complications must also be provided with the medication (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated (cervix, rectum [off-label use], urethra):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dual therapy regimen (preferred) <i>(off-label)</i>:</i> 1 g as a single dose in combination with ceftriaxone (preferred) or cefixime (only if ceftriaxone unavailable) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with severe cephalosporin allergy (off-label):</i> 2 g as a single dose in combination with gemifloxacin or gentamicin IM (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment failure </i>\n      <i>(off-label): </i>2 g as a single dose in combination with gemifloxacin, gentamicin, or ceftriaxone (regimen varies considerably depending on the failed initial dual therapy regimen, susceptibilities of isolate, and geographic location (CDC [Workowski 2015]; WHO [<i>Neisseria gonorrhoeae</i> 2016]). <b>Note</b>: If re-infection (more common than treatment failure) or patient did not receive preferred dual therapy regimen initially, consider treating with preferred dual therapy regimen first. Consult an infectious diseases specialist when treatment failure is suspected and report failures to the CDC (telephone: 404-639-8650), and state and local health departments (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated (pharynx) (off-label use):</b> Oral: 1 g as a single dose in combination with ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Granuloma inguinale (donovanosis) (off-label use):</b> Oral: 1 g once weekly <b>or</b> 500 mg once daily for at least 3 weeks and until lesions have healed. <b>Note:</b> If symptoms do not improve within the first few days of therapy, the addition of gentamicin may be considered (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i> infection (off-label use):</b> Oral: 500 mg once daily for 3 to 7 days in combination with an acid-reducing drug and other antibiotics (Laine 1999; Trevisani 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infection prophylaxis in neutropenia (off-label use):</b> Oral: 250 mg once daily; initiate at the time of stem cell infusion and continue until recovery from neutropenia or initiation of empiric antibiotics for neutropenic fever (IDSA [Freifeld 2011]; Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (erythema migrans or borrelial lymphocytoma) (off-label use):</b> Oral: 500 mg once daily for 7 to 10 days (IDSA [Wormser 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate respiratory tract, skin, and soft tissue infections:</b> Oral: 500 mg in a single loading dose on day 1 followed by 250 mg daily as a single dose on days 2 to 5</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative regimen:</i> Bacterial exacerbation of COPD: 500 mg daily for a total of 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium avium</i> complex (MAC) infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Disseminated disease in HIV-infected patients</i> (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 500 to 600 mg daily in combination with ethambutol</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary prophylaxis (patients with CD4 count &lt;50 cells/mm<sup>3</sup>): 1,200 mg once weekly (preferred) <b>or</b> 600 mg twice weekly; may discontinue prophylaxis when CD4 count &gt;100 cells/mm<sup>3</sup> for &ge;3 months in response to antiretroviral therapy (ART).<b> Note:</b> If effective ART is initiated immediately and viral suppression is achieved, some experts do not recommend routine initiation of MAC primary prophylaxis, regardless of initial CD4 count (IAS-USA [G&uuml;nthard 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary prophylaxis: 500 to 600 mg daily in combination with ethambutol; may discontinue when patient has completed &ge;12 months of therapy, has no signs/symptoms of MAC disease, and has sustained (&gt;6 months) CD4 count &gt;100 cells/mm<sup>3</sup> in response to ART</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary disease (nodular/bronchiectatic disease) in non-HIV-infected patients (off-label use):</i> 500 to 600 mg 3 times weekly in combination with rifampin and ethambutol; continue treatment until patient is culture negative on therapy for 1 year (ATS/IDSA [Griffith 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary disease (severe nodular/bronchiectatic or cavitary disease) in non-HIV-infected patients (off-label use)</i>: 250 to 300 mg once daily in combination with a rifamycin plus ethambutol; continue treatment until patient is culture negative on therapy for 1 year. May also consider addition of 3-times-weekly amikacin or streptomycin early in therapy (ATS/IDSA [Griffith 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary disease in patients with cystic fibrosis (off-label use)</i>: 250 to 500 mg once daily in combination with rifampin and ethambutol; continue for 12 months beyond culture conversion. <b>Note:</b> Intermitted dosing (3 times weekly) is not recommended for patients with cystic fibrosis (Floto 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycoplasma genitalium</i> (off-label use)</b> (Falk 2015; CDC [Workowski 2015]): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose regimen:</i> 1 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-dose regimen:</i> 500 mg on day 1, followed by 250 mg once daily on days 2 through 5</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nontuberculous mycobacterial disease (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mycobacterium abscessus</i> pulmonary disease in patients with cystic fibrosis: 250 to 500 mg once daily in combination with amikacin plus one or more additional IV antibiotic based on tolerability and drug susceptibility for 3 to 12 weeks, followed by a continuation phase of azithromycin 250 to 500 mg once daily in combination with inhaled amikacin with 2 to 3 additional antibiotics (eg, minocycline, clofazimine, moxifloxacin, linezolid) (Floto 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. abscessus</i> skin, soft tissue, or bone infections: 250 mg once daily in combination with an IV antibiotic (eg, amikacin, cefoxitin, imipenem); duration depends on severity and site of infection (ATS/IDSA [Griffith 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (PID):</b> IV: 500 mg as a single dose for 1 to 2 days, follow IV therapy by the oral route with a single daily dose of 250 mg to complete a 7-day course of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pertussis (off-label use) (CDC 2005):</b> Oral: 500 mg on day 1 followed by 250 mg daily on days 2 to 5 (maximum: 500 mg daily).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis (including susceptible group A streptococci), tonsillitis (as an alternative agent in penicillin-allergic patients):</b> Oral: 12 mg/kg (maximum: 500 mg) on day 1 followed by 6 mg/kg (maximum: 250 mg) once daily on days 2 through 5. <b>Note:</b> Regimen is also recommended by the Infectious Disease Society of America (IDSA) (Shulman 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired: </b>\n      <b>Note:</b> For empiric therapy, may need to use in combination with other appropriate agents (depending on disease severity and/or risk factors for drug-resistant pathogens). Treat for &ge;5 days (patients should be afebrile for 48 to 72 hours and clinically stable prior to discontinuation) (IDSA/ATS [Mandell 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Outpatient: 500 mg on day 1 followed by 250 mg once daily on days 2 to 5. More severe pneumonia (requiring inpatient treatment) should be treated with 500 mg once daily for duration of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ER suspension (Zmax): 2 g as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, IV: Inpatient: 500 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of exacerbations of chronic obstructive pulmonary disease (COPD) (off-label use): </b>Oral: 250 mg once daily (Albert 2011) or 500 mg 3 times weekly (Uzun 2014). <b>Note: </b>Duration of prophylaxis in clinical studies was 1 year (Albert 2011; Uzun 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of pulmonary exacerbations in patients with noncystic fibrosis bronchiectasis (off-label use):</b> Oral: 500 mg 3 days per week. <b>Note:</b> Duration of treatment in clinical trial was 6 months; durations &gt;6 months have not been evaluated. Trial patients had &ge;1 exacerbation in the past year, no macrolide treatment for &gt;3 months in the past 6 months, and were screened for nontuberculous mycobacterial infection prior to treatment (Wong 2012). A more selective approach for patients with functionally mild disease has been suggested (Wilson 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b> Oral: 500 mg 30 to 60 minutes prior to the procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> Oral: 1 g as a single dose in combination with ceftriaxone (plus metronidazole or tinidazole) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Shigella dysentery type 1 (off-label use):</b> Oral: 1,000 to 1,500 mg once daily for 1 to 5 days (WHO 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis, primary and secondary (off-label use): </b>Oral: 2,000 mg as a single dose. <b>Note: </b>Because of the possibility of resistance and treatment failure, azithromycin should be used with caution and should not be used to treat syphilis in patients with HIV, pregnant women, or in the MSM population (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Toxoplasma gondii </i>encephalitis (treatment) in HIV-infected patients (off-</b>\n      <b>label use)</b>: Oral: 900 to 1,200 mg once daily in combination with pyrimethamine and leucovorin for at least 6 weeks, followed by a chronic maintenance therapy regimen (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler&rsquo;s diarrhea (off-label use):</b> Oral: 1,000 mg as a single dose <b>or</b> 500 mg once daily for 3 days (ACG [Riddle 2016]; CDC 2018; Riddle 2017; Tribble 2007). If symptoms not resolved after 24 hours following single dose therapy, continue with 500 mg once daily for 2 more days. A 3-day course of 500 mg daily is the preferred regimen for dysentery or febrile diarrhea (ACG [Riddle 2016]). Adjunctive loperamide may be considered in patients receiving antibiotic therapy, in particular for immunocompetent adults with acute watery diarrhea (ACG [Riddle 2016]; IDSA [Shane 2017]; Riddle 2017). <b>Note:</b> Increased nausea may occur with the 1,000 mg single-dose regimen (Tribble 2007). Nausea may be reduced by administering as 2 divided doses (CDC 2018; Riddle 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis/cervicitis (nongonococcal):</b> Oral: 1 g as a single dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983293\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=azithromycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Azithromycin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Extended release suspension (Zmax) is not interchangeable with immediate release formulations.</b> Use should be limited to approved indications. All doses are expressed as immediate release azithromycin unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Adolescents &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acne vulgaris (off-label use):</b> Adolescents &ge;13 years: Oral: Dosing regimens used in clinical trials have varied greatly. All trials used pulse-dosing regimens; regimens include: 500 mg once daily for 4 consecutive days per month for 3 consecutive months (Babaeinejad 2011) <b>or</b> 500 mg once daily for 3 days in the first week, followed by 500 mg once weekly until week 10 (Maleszka 2011). The shortest possible duration should be used to minimize development of bacterial resistance; re-evaluate at 3 to 4 months (AAD [Zaenglein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial sinusitis:</b> Children &ge;6 months: Oral: 10 mg/kg once daily for 3 days (maximum: 500 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cat scratch disease (off-label use) (Bass 1998; Stevens 2014): </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;45.5 kg: 10 mg/kg as a single dose, then 5 mg/kg once daily for 4 additional days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;45.5 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Chlamydia trachomatis </b></i>\n      <b>infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cervicitis, urethritis (off-label):</i> Children &ge;45 kg: 1 g as a single dose (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conjunctivitis (off-label use; alternative agent):</i> Infants: 20 mg/kg once daily for 3 days (CDC [Workowski 2015]; WHO [<i>Chlamydia</i> 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (CAP) (IDSA/PIDS 2011):</b> Infants &gt;3 months and Children: <b>Note:</b> A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Presumed mild infection or step-down therapy, atypical <i>(M. pneumoniae, Chlamydophila</i> [also known as <i>Chlamydia</i>] <i>pneumoniae, C. trachomatis)</i> (preferred): Oral: 10 mg/kg (maximum dose: 500 mg) as a single dose on the first day, followed by 5 mg/kg/day (maximum dose: 250 mg) on days 2 through 5</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Presumed moderate to severe infection, atypical <i>(M. pneumoniae, Chlamydophila</i> [also known as <i>Chlamydia</i>] <i>pneumoniae, C. trachomatis)</i>: IV: 10 mg/kg/day on days 1 and 2, then switch to oral azithromycin therapy if possible to finish the 5-day course</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative regimens for community-acquired pneumonia:</i> Oral: 10 mg/kg (maximum dose: 500 mg) once daily for 3 days (Kogan 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release suspension (Zmax): Infants &ge;6 months and Children: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;75 lbs (34 kg): 60 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;75 lbs (34 kg): Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Disseminated </b> <b><i>M. avium </i></b><b>complex disease in patients with advanced HIV infection (off-label use) (DHHS 2013):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 10 to 12 mg/kg/day (maximum: 500 mg) in combination with ethambutol; patients with severe disease should also receive rifabutin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prophylaxis:</i> 20 mg/kg (maximum: 1,200 mg) once weekly (preferred) or alternatively, 5 mg/kg/day once daily (maximum: 250 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary prophylaxis:</i> 5 mg/kg/day once daily (maximum: 250 mg daily) in combination with ethambutol, with or without rifabutin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, conjunctivitis (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, disseminated (arthritis, arthritis-dermatitis, meningitis, endocarditis) (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated (cervix, rectum [off-label use], urethra) (off-label regimen):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infection, uncomplicated (pharynx) (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media:</b> Children &ge;6 months: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>1-day regimen:</i> 30 mg/kg as a single dose (maximum dose: 1,500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>3-day regimen:</i> 10 mg/kg once daily for 3 days (maximum: 500 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>5-day regimen:</i> 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day once daily on days 2 to 5 (maximum: 250 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pertussis (off-label use) (CDC 2005):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;6 months: 10 mg/kg/day for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 months: 10 mg/kg on day 1 (maximum: 500 mg daily) followed by 5 mg/kg/day once daily on days 2 to 5 (maximum: 250 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis (including susceptible group A streptococci), tonsillitis (as an alternative agent in penicillin allergic patients):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling and AHA/AAP recommendations: Children &ge;2 years and Adolescents: Oral: 12 mg/kg/dose once daily for 5 days (maximum: 500 mg daily) (AHA guidelines [Gerber 2009]; <i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternative recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (off-label dose/regimen): Oral: Suspension: 20 mg/kg once daily for 3 days (maximum dose/day: 1,000 mg) (Cohen 2004; O&rsquo;Doherty 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Oral: 12 mg/kg (maximum: 500 mg) on day 1 followed by 6 mg/kg/dose (maximum: 250 mg) once daily on days 2 through 5 (IDSA guidelines [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against infective endocarditis (off-label use):</b> Oral: 15 mg/kg 30 to 60 minutes before procedure. <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Shigella dysentery type 1 (off-label use):</b> Oral: 6 to 20 mg/kg/day for 1 to 5 days (WHO 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983295\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983296\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use with caution in patients with GFR &lt;10 mL/minute (AUC increased by 35% compared to patients with normal renal function); however, no dosage adjustment is provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007; Heintz 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983297\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Azithromycin is predominantly hepatically eliminated; however, there is no dosage adjustment provided in the manufacturer's labeling, Use with caution due to potential for hepatotoxicity (rare); discontinue immediately for signs or symptoms of hepatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983340\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 1 g (3 ea, 10 ea) [cherry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (3 ea, 10 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 2.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 100 mg/5 mL (15 mL) [cherry-vanilla-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 200 mg/5 mL (15 mL, 22.5 mL, 30 mL) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zmax: 2 g (1 ea) [cherry-banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax: 250 mg, 500 mg, 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax Tri-Pak: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax Z-Pak: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983186\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983300\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Infuse over 1 hour (2 mg/ml infusion) or over 3 hours (1 mg/ml infusion). Not for IM or IV bolus administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Immediate release suspension and tablet may be taken without regard to food; extended release suspension should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal), within 12 hours of reconstitution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983211\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial exacerbations of chronic obstructive pulmonary disease:</b> Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to <i>Haemophilus influenzae, Moraxella catarrhalis</i>, or <i>Streptococcus pneumoniae</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute otitis media:</b> Treatment of acute otitis media due to <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial sinusitis, acute:</b> Treatment of acute bacterial sinusitis due to <i>H. influenzae, M. catarrhalis,</i> or <i>S. pneumoniae</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chancroid:</b> Treatment of genital ulcer disease (in men) due to <i>Haemophilus ducreyi</i> (chancroid)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium avium</i> complex (MAC):</b> Prevention of MAC (alone or in combination with rifabutin) in patients with advanced HIV infection; treatment of disseminated MAC (in combination with ethambutol) in patients with advanced HIV infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> Treatment of pelvic inflammatory disease (PID) due to <i>Chlamydia trachomatis, Neisseria gonorrhoeae,</i> or <i>Mycoplasma hominis</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis:</b> Treatment of pharyngitis/tonsillitis due to <i>Streptococcus pyogenes</i> as an alternative to first-line therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired:</b> Treatment of community-acquired pneumonia due to <i>Chlamydophila pneumoniae, H. influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae,</i> or <i>S. pneumoniae</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection, uncomplicated:</b> Treatment of uncomplicated skin and skin structure infections due to <i>Staphylococcus aureus, S. pyogenes</i>, or <i>Streptococcus agalactiae</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urethritis/cervicitis:</b> Treatment of urethritis and cervicitis due to <i>C. trachomatis</i> or <i>N. gonorrhoeae</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475163\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acne vulgaris; Babesiosis; Bronchiolitis obliterans syndrome; Cat scratch disease; Cesarean section (nonelective), prophylaxis (preoperative); Chlamydia trachomatis conjunctivitis (infants); Cholera; Gonococcal conjunctivitis; Gonococcal, disseminated infections (arthritis, arthritis-dermatitis syndrome, meningitis, and endocarditis); Gonococcal infection, expedited partner therapy; Gonococcal, uncomplicated infections of the pharynx or rectum; Granuloma inguinale (donovanosis); Group A streptococcal pharyngitis (children); 3-day regimen; Helicobacter pylori infection; Infection prophylaxis in neutropenia (adults); Infective endocarditis (prophylaxis); Lyme disease; Mycobacterium avium complex, pulmonary disease, in non-HIV-infected patients:; Mycoplasma genitalium; Nontuberculous mycobacterial disease; Prevention of exacerbations of chronic obstructive pulmonary disease (COPD); Prevention of pulmonary exacerbations with noncystic fibrosis bronchiectasis; Prophylaxis against sexually transmitted diseases following sexual assault; Shigella dysenteriae type 1; Syphilis, primary and secondary; Traveler&rsquo;s diarrhea; Toxoplasma gondii encephalitis (treatment) in HIV-infected patients (adults and adolescents); Pertussis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983163\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azithromycin may be confused with azathioprine, erythromycin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zithromax may be confused with Fosamax, Zinacef, Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983244\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Loose stools (&le;14%; single-dose regimens tend to be associated with increased incidence), vomiting (children, single-dose regimens tend to be associated with increased incidence: 1% to 14%; adults: &le;2%; adults, single 2 g dose: 1% to 7%), diarrhea (2% to 9%; single-dose regimens 4% to 14%), nausea (&le;7%; high single-dose regimens 4% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (&le;1%), palpitations (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;1%), drowsiness (&le;1%), fatigue (&le;1%), headache (&le;1%), vertigo (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;5%; single-dose regimens tend to be associated with increased incidence), dermatitis (children: &le;2%), pruritus (&le;2%), skin photosensitivity (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (1% to 3%), increased gamma-glutamyl transferase (1% to 2%), increased serum potassium (1% to 2%), decreased serum bicarbonate (adults: &ge;1%), decreased serum glucose (adults: &gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (1% to 7%; single-dose regimens tend to be associated with increased incidence), anorexia (&le;2%), dysgeusia (&le;1%), dyspepsia (&le;1%), flatulence (&le;1%), gastritis (&le;1%), melena (adults, multiple-dose regimens: &le;1%), mucositis (&le;1%), oral candidiasis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginitis (&le;3%), genital candidiasis (adults, multiple-dose regimens: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decrease in absolute neutrophil count (children: 15% to 16%; 500 to 1,500 cells/mm<sup>3</sup>), decreased hematocrit (adults: &gt;1%), decreased hemoglobin (adults: &gt;1%), increased neutrophils (adults: &gt;1%), thrombocythemia (adults: &gt;1%), change in neutrophil count (children: &ge;1%), eosinophilia (&ge;1%), lymphocytopenia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&le;6%), increased serum AST (&le;6%), increased serum bilirubin (&le;3%), cholestatic jaundice (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local (adults with IV administration): Pain at injection site (7%), local inflammation (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&le;6%), increased blood urea nitrogen (&le;1%), nephritis (adults, multiple-dose regimens: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchospasm (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children: (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal stools, acute generalized exanthematous pustulosis, acute renal failure, ageusia, aggressive behavior, agitation, alteration in sodium, altered sense of smell, altered serum glucose, anaphylaxis, anemia, angioedema, anosmia, anxiety, arthralgia, asthma, basophilia, bronchitis, cardiac arrhythmia, chills, <i>Clostridium difficile</i> associated diarrhea, conjunctivitis (children), constipation, convulsions, cough, deafness, decreased serum potassium (children), decreased serum sodium, diaphoresis, DRESS syndrome, dyspnea, dysuria, eczema, edema, emotional lability, enteritis, erythema multiforme, exacerbation of myasthenia gravis, facial edema, flu-like symptoms, fungal dermatitis, fungal infection, gastrointestinal disease, hearing loss, hepatic failure, hepatic insufficiency, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hostility, hyperactivity, hyperkinesia, hypersensitivity reaction, hypotension, increased monocytes, increased serum alkaline phosphatase, increased serum bicarbonate, increased serum glucose, increased serum phosphate, interstitial nephritis, insomnia, irritability, jaundice, Lambert-Eaton syndrome, leukopenia, maculopapular rash, malaise, nervousness, neutropenia , otitis media, pain, pancreatitis, paresthesia, pharyngitis, pleural effusion, prolonged Q-T interval on ECG , pseudomembranous colitis, pyloric stenosis, pyloric stenosis (infantile hypertrophic), rhinitis, seizure, Stevens-Johnson syndrome, syncope, thrombocytopenia, tinnitus, tongue discoloration, torsades de pointes toxic epidermal necrolysis, urticaria, ventricular tachycardia, vesiculobullous dermatitis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983221\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to azithromycin, erythromycin, other macrolide (eg, azalide or ketolide) antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> The manufacturer does not list concurrent use of pimozide as a contraindication; however, azithromycin is listed as a contraindication in the manufacturer&rsquo;s labeling for pimozide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983222\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Allergic reactions (eg, angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported (rare), including fatalities; reappearance of allergic reaction may occur shortly after discontinuation of symptomatic treatment without further azithromycin exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Macrolides (especially erythromycin) have been associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes; consider avoiding use in patients with prolonged QT interval, congenital long QT syndrome, history of torsade de pointes, bradyarrhythmias, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, uncompensated heart failure, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents or other drugs known to prolong the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac risk: A retrospective cohort study done in Tennessee Medicaid patients demonstrated an increased cardiac risk with azithromycin relative to amoxicillin or ciprofloxacin, and similar risk compared to levofloxacin; notably, increased cardiac mortality (an estimated 47 additional deaths per 1 million 5-day courses of treatment compared to amoxicillin) was associated with higher baseline cardiovascular risk (Ray 2012); however, these data may not be generalizable to the population as a whole (Ray 1989). In another retrospective population study of US veterans, azithromycin was shown to significantly increase the risk of mortality and arrhythmia on days 1 to 5, but not on days 6 to 10 after dispensing the prescription (Rao 2014). In contrast, 2 additional large retrospective cohort studies did <b>not</b> demonstrate an increased risk of cardiovascular events, including all-cause mortality or cardiovascular death (Svanstrom 2013, Mortensen 2014). The implications of these data have yet to be determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gonorrhea/syphilis: May mask or delay symptoms of incubating gonorrhea or syphilis, so appropriate culture and susceptibility tests should be performed prior to initiating a treatment regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with preexisting liver disease; hepatocellular and/or cholestatic hepatitis, with or without jaundice, hepatic necrosis, failure, and death have occurred. Discontinue immediately if symptoms of hepatitis occur (malaise, nausea, vomiting, abdominal colic, fever).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation and new onset of symptoms have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (GFR &lt;10 mL/minute); increased gastrointestinal adverse effects may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infants: Use of azithromycin in neonates and infants (treatment up to 42 days of life) has been associated with infantile hypertrophic pyloric stenosis (IHPS); observe for non-bilious vomiting or irritability with feeding (Eberly 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral suspensions: Immediate release and extended release suspensions are not interchangeable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983249\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983250\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8868&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Azithromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone.  Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Azithromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivermectin (Systemic): Azithromycin (Systemic) may increase the serum concentration of Ivermectin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Azithromycin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Azithromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983254\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rate and extent of GI absorption may be altered depending upon the formulation. Azithromycin suspension, not tablet form, has significantly increased absorption (46%) with food. Management: Immediate release suspension and tablet may be taken without regard to food; extended release suspension should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983214\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983215\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Azithromycin crosses the placenta (Ramsey 2003). The maternal serum half-life of azithromycin is unchanged in early pregnancy and decreased at term; however, high concentrations of azithromycin are sustained in the myometrium and adipose tissue (Fischer 2012; Ramsey 2003). Azithromycin is recommended for the treatment of several infections, including chlamydia, gonococcal infections, and <i>Mycobacterium avium</i> complex (MAC) in pregnant patients (consult current guidelines) (CDC [Workowski 2015]; HHS [opportunistic; adult] 2015). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983220\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Azithromycin is excreted in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of azithromycin is 4% to 8% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 5 to 10 mg/kg/day. In general, breast-feeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (2.8 mcg/mL), the estimated daily infant dose via breast milk is 0.42 mg/kg/day. This milk concentration was obtained following maternal administration of oral azithromycin as a 1 g loading dose followed in 48 hours by azithromycin 500 mg for 3 days; milk concentrations increased over time and reached a peak 30 hours after the last oral dose (Kelsey 1994).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following a single dose of IV azithromycin 500 mg, azithromycin was measurable in breast milk for up to 48 hours. The median half-life in breast milk was 15.6 hours (Sutton 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Decreased appetite, diarrhea, rash, and somnolence have been reported in nursing infants exposed to macrolide antibiotics (Goldstein 2009). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002). In addition, an increased risk for infantile hypertrophic pyloric stenosis (IHPS) may be present in infants who are exposed to macrolides via breast milk, especially during the first 2 weeks of life (Lund 2014); however, data is conflicting (Goldstein 2009). The manufacturer recommends that caution be exercised when administering azithromycin to breast-feeding women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The CDC's Sexually Transmitted Diseases Treatment Guidelines state that azithromycin is one of the recommended agents for the treatment of granuloma inguinale in lactating women. For lymphogranuloma venereum, azithromycin may be considered as an alternative agent in this patient population (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983299\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;\">Some products may contain sodium and/or sucrose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension, immediate release, may be administered with or without food. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension, extended release, should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet may be administered with food to decrease GI effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983325\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, CBC with differential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983260\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983262\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid from the GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive tissue; distributes well into skin, lungs, sputum, tonsils, and cervix; penetration into CSF is poor; V<sub>d</sub>: 31 to 33 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding (concentration dependent and dependent on alpha1-acid glycoprotein concentrations): Oral, IV: 7% to 51% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Tablet, immediate release oral suspension: 34% to 52%; extended release oral suspension: 28% to 43%; variable effect with food (increased with immediate or delayed release oral suspension, unchanged with tablet) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Oral, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 4 months to 15 years: 54.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: 68 to 72 hours; Extended release: 59 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Immediate release: ~2 to 3 hours; Extended release: 3 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral, IV: Biliary (major route 50%, unchanged); urine (6% to 14% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983342\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (3): $87.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (3): $442.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Azithromycin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zithromax Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (15 mL): $34.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (30 mL): $34.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (15 mL): $174.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (22.5 mL): $174.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Zmax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $160.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azithromycin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (6): $46.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (3): $46.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (30): $560.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $1,235.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $2,471.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (30): $2,965.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Tri-Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (3): $247.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zithromax Z-Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (6): $247.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961955\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ajustin (KR);</li>\n      <li>Aratro (ES);</li>\n      <li>Atizor (CL);</li>\n      <li>ATM-200 (TZ);</li>\n      <li>Aza-250 (HK);</li>\n      <li>Aza-500 (HK);</li>\n      <li>Azadose (FR);</li>\n      <li>Azas (KR);</li>\n      <li>Azath (KR);</li>\n      <li>Azatril (EE, VN);</li>\n      <li>Azax (TR);</li>\n      <li>Azbact (LK);</li>\n      <li>Azce (LK);</li>\n      <li>Azee (HK);</li>\n      <li>Azeemycin (PH);</li>\n      <li>Azenil (IL);</li>\n      <li>Azi-500 (PH);</li>\n      <li>Azibact (DE, IN);</li>\n      <li>Azibiot (LV, RO);</li>\n      <li>Azicine (HK, MY, VN);</li>\n      <li>Azilide-250 (PH);</li>\n      <li>Azilide-500 (PH);</li>\n      <li>Azimac (SA);</li>\n      <li>Azimax (MY);</li>\n      <li>Azimax-250 (HK, SG);</li>\n      <li>Azimed (HR);</li>\n      <li>Azin (BD, PH);</li>\n      <li>Azinobin (CO);</li>\n      <li>Aziphar (VN);</li>\n      <li>Azirocin (KR);</li>\n      <li>Azith (AU, TH);</li>\n      <li>Azithral (IN);</li>\n      <li>Azithrin (MT);</li>\n      <li>Azithro (MY);</li>\n      <li>Azithrom (TW);</li>\n      <li>Azitops (KR);</li>\n      <li>Azitrex (EC);</li>\n      <li>Azitrix (PT);</li>\n      <li>Azitrocin (IT, PH);</li>\n      <li>Azitromax (NO, SE);</li>\n      <li>Azitrox (SK);</li>\n      <li>Aziwok (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Azm (LK);</li>\n      <li>Azo-500 (PH);</li>\n      <li>Azomax (BH, KW);</li>\n      <li>Azomycin (AE, KW, QA, SA);</li>\n      <li>Azomyne (JO, LB, QA);</li>\n      <li>Azox (JO);</li>\n      <li>Azro (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Azromax (IE);</li>\n      <li>Aztrin (ID);</li>\n      <li>Azyth (PH);</li>\n      <li>Azytsyn (UA);</li>\n      <li>Binozyt (HK, KR, LK, SG, TH, VN);</li>\n      <li>Clindal AZ (BR, HK);</li>\n      <li>Cronopen (AR);</li>\n      <li>Decantin (PH);</li>\n      <li>Floctil (HK, MY, TH);</li>\n      <li>Geozif (VN);</li>\n      <li>Geozit (PH);</li>\n      <li>Glazi (VN);</li>\n      <li>Imexa (HK, MY);</li>\n      <li>Inedol (PE);</li>\n      <li>Jazit (PH);</li>\n      <li>Koptin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kromicin (CO);</li>\n      <li>Macromax (PH);</li>\n      <li>Macrozit (CO, PE);</li>\n      <li>Maxmor (ID);</li>\n      <li>Mazit (QA);</li>\n      <li>Meithromax (TH);</li>\n      <li>Mezatrin (ID);</li>\n      <li>Neazi (VN);</li>\n      <li>OD Mac (PH);</li>\n      <li>Odazyth (BD);</li>\n      <li>Onzet (TH);</li>\n      <li>Ormaks (UA);</li>\n      <li>Shepherd (CN);</li>\n      <li>Sumamed (BG, CN, CZ, EE, LV, PL, SK);</li>\n      <li>Thromaxin (PH);</li>\n      <li>Tromix (CO);</li>\n      <li>Ultreon (DE);</li>\n      <li>Uzet (LK);</li>\n      <li>Vinzam (BD);</li>\n      <li>Weihong (CN);</li>\n      <li>Wiltrozin (PH);</li>\n      <li>Xithrone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Zaha-250 (TZ);</li>\n      <li>Zaret (CO);</li>\n      <li>Zarom (ID);</li>\n      <li>Zedbac (GB);</li>\n      <li>Zedd (AU);</li>\n      <li>Zemax (TH);</li>\n      <li>Zenith (PH);</li>\n      <li>Zeto (IL);</li>\n      <li>Zetron (LB, QA);</li>\n      <li>Zicho (ID);</li>\n      <li>Zimac (SA);</li>\n      <li>Zimax (LB);</li>\n      <li>Zimericina (CO);</li>\n      <li>Zinfect (TR);</li>\n      <li>Zistic (ID);</li>\n      <li>Zitaspen (ZW);</li>\n      <li>Zithrax (ID);</li>\n      <li>Zithromac SR (JP);</li>\n      <li>Zithromax (AE, AT, AU, BB, BD, BF, BH, BJ, CH, CI, CL, CN, CR, CY, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Zithromax IV (MY, SG);</li>\n      <li>Zithrox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LK, LY, OM, SA, SY, YE);</li>\n      <li>Zitrim (CO);</li>\n      <li>Zitrocin (PY);</li>\n      <li>Zitrolin (ID);</li>\n      <li>Zitromax (AR, BE, BR, DK, EC, ES, IS, IT, LU, PE, TR, UY, VE);</li>\n      <li>Zmax (IL, SG, ZW);</li>\n      <li>Zmax One Dose (PH);</li>\n      <li>Zocin (AE, JO, QA);</li>\n      <li>Zomax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zymed (ID);</li>\n      <li>Zynomax (MY);</li>\n      <li>Zythrocin (TW);</li>\n      <li>Zytroks (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21864166\"></a>Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. <i>N Engl J Med</i>. 2011;365(8):689-698.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/21864166/pubmed\" target=\"_blank\" id=\"21864166\">21864166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin No. 120: Use of Prophylactic Antibiotics in Labor and Delivery,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1472-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &quot;Combating Antibiotic Resistance,&quot; <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/15127872/pubmed\" target=\"_blank\" id=\"15127872\">15127872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 58, 151.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Babaeinejad S, Khodaeiani E, Fouladi RF. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: What is the role of age? <i>J Dermatolog Treat</i>. 2011;22(4):206-210. doi: 10.3109/09546631003762639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/20666686/pubmed\" target=\"_blank\" id=\"20666686\">20666686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9655532\"></a>Bass JW, Freitas BC, Freitas AD, et al, &ldquo;Prospective Randomized Double Blind Placebo-Controlled Evaluation of Azithromycin for the Treatment of Cat-Scratch Disease,&rdquo; <i>Pediatr Infect Dis J</i>, 1998, 17(6):447-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/9655532/pubmed\" target=\"_blank\" id=\"9655532\">9655532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Accessed September 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-14):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/16340941/pubmed\" target=\"_blank\" id=\"16340941\">16340941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coates P, Daniel R, Houston AC, et al, &ldquo;An Open Study to Compare the Pharmacokinetics, Safety, and Tolerability of a Multiple-Dose Regimen of Azithromycin in Young and Elderly Volunteers,&rdquo; <i>Eur J Clin Microbiol Infect Dis</i>, 1991, 10(10):850-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/1662630/pubmed\" target=\"_blank\" id=\"1662630\">1662630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. <i>Pediatr Infect Dis J</i>. 2004;23(2 Suppl):S129-S134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/14770076/pubmed\" target=\"_blank\" id=\"14770076\">14770076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cotter CJ and Bierne JC, &quot;Azithromycin for Odontogenic Infection,&quot; <i>J Oral Maxillofac Surg</i><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/14586869/pubmed\" target=\"_blank\" id=\"14586869\">14586869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eberly MD, Eide MB, Thompson JL, et al. Azithromycin in early infancy and pyloric stenosis. <i>Pediatrics</i>. 2015;135(3):483-488. doi: 10.1542/peds.2014-2026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/25687145/pubmed\" target=\"_blank\" id=\"25687145\">25687145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falk L, Enger M, Jensen JS. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. <i>J Antimicrob Chemother</i>. 2015;70(11):3134-3140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/26283670/pubmed\" target=\"_blank\" id=\"26283670\">26283670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer JH, Sarto GE, Habibi M, et al, &quot;Influence of Body Weight, Ethnicity, Oral Contraceptives, and Pregnancy on the Pharmacokinetics of Azithromycin in Women of Childbearing Age,&quot; <i>Antimicrob Agents Chemother</i>, 2012, 56(2):715-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22106226/pubmed\" target=\"_blank\" id=\"22106226\">22106226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(Suppl 1):1-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22106226/pubmed\" target=\"_blank\" id=\"22106226\">22106226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foulds G, Shepard RM, and Johnson RB, &ldquo;The Pharmacokinetics of Azithromycin in Human Serum and Tissues,&rdquo; <i>J Antimicrob Chemother</i>, 1990, 25(Suppl A):73-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/2154441/pubmed\" target=\"_blank\" id=\"2154441\">2154441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. <i>Clin Infect Dis</i>. 2011 Feb 15;52(4):e56-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551. doi: 10.1161/CIRCULATIONAHA.109.191959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghanem KG and Workowski KA, &ldquo;Management of Adult Syphilis,&rdquo; <i>Clin Infect Dis</i>, 2011, 53(Suppl 3):110-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22080265/pubmed\" target=\"_blank\" id=\"22080265\">22080265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, et al, &quot;The Safety of Macrolides During Lactation,&quot; <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18192909\"></a>Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. <i>Transplantation</i>. 2008;85(1):36-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/18192909/pubmed\" target=\"_blank\" id=\"18192909\">18192909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17277290\"></a>Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <i>Am J Respir Crit Care Med</i>. 2007;175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DR, &ldquo;Pharmacokinetics of the New Macrolides,&rdquo; <i>Infect Med</i>, 1992, 9:9-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&uuml;nthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. <i>JAMA</i>. 2016;316(2):191-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27404187/pubmed\" target=\"_blank\" id=\"27404187\">27404187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoffler D, Koeppe P, and Paeske B, &ldquo;Pharmacokinetics of Azithromycin in Normal and Impaired Renal Function,&rdquo; <i>Infection</i>, 1995, 23(6):356-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/8655206/pubmed\" target=\"_blank\" id=\"8655206\">8655206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated July 14, 2016. Accessed January 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20133163\"></a>Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. <i>J Heart Lung Transplant</i>. 2010;29(5):531-537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/20133163/pubmed\" target=\"_blank\" id=\"20133163\">20133163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan JE, Benson C, Holmes KH, et al, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo; <i>MMWR Recomm Rep</i>, 2009, 58(4):1-207.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelsey JJ, Moser LR, Jennings JC, et al, &quot;Presence of Azithromycin Breast Milk Concentrations: A Case Peport,&quot; <i>Am J Obstet Gynecol</i>, 1994, 170(5 Pt 1):1375-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/8178871/pubmed\" target=\"_blank\" id=\"8178871\">8178871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim MH, Berkowitz C, and Trohman RG, &quot;Polymorphic Ventricular Tachycardia With a Normal QT Interval Following Azithromycin,&quot; <i>Pacing Clin Electrophysiol</i>, 2005, 28(11):1221-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/16359290/pubmed\" target=\"_blank\" id=\"16359290\">16359290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kogan R, Mart&iacute;nez MA, Rubilar L, et al, &ldquo;Comparative Randomized Trial of Azithromycin versus Erythromycin and Amoxicillin for Treatment of Community-acquired Pneumonia in Children,&rdquo; <i>Pediatr Pulmonol</i>, 2003, 35(2):91-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/12526069/pubmed\" target=\"_blank\" id=\"12526069\">12526069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11078770\"></a>Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. <i>N Engl J Med</i>. 2000;343:1454-1458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/11078770/pubmed\" target=\"_blank\" id=\"11078770\">11078770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. <i>Clin Exp Dermatol</i>. 2005;30(3):215-220. doi: 10.1111/j.1365-2230.2005.01769.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/15807672/pubmed\" target=\"_blank\" id=\"15807672\">15807672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laine L, Estrada R, Trujillo M, et al. Once-daily therapy for <i>H. pylori</i> infection: a randomized comparison of four regimens. <i>Am J Gastroenterol</i>. 1999;94(4):962-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/15807672/pubmed\" target=\"_blank\" id=\"15807672\">15807672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lockwood AM, Cole S, and Rabinovich M, &quot;Azithromycin-Induced Liver Injury,&quot; <i>Am J Health Syst Pharm</i>, 2010, 67(10):810-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/20479103/pubmed\" target=\"_blank\" id=\"20479103\">20479103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. <i>BMJ</i>. 2014;348:1908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24618148/pubmed\" target=\"_blank\" id=\"24618148\">24618148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maleszka R, Turek-Urasinska K, Oremus M, Vukovic J, Barsic B. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study. <i>Skinmed</i>. 2011;9(2):86-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/21548512/pubmed\" target=\"_blank\" id=\"21548512\">21548512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(Suppl 2):S27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25359357\"></a>Meyer KC, Raghu G, Verleden GM, et al; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. <i>Eur Respir J</i>. 2014;44(6):1479-1503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/25359357/pubmed\" target=\"_blank\" id=\"25359357\">25359357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. <i>JAMA</i>. 2014;311(21):2199-2208. doi:10.1001/jama.2014.4304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24893087/pubmed\" target=\"_blank\" id=\"24893087\">24893087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Koranyi KI, Gadgil SD, et al, &ldquo;Pharmacokinetics of Azithromycin After Oral Administration of Multiple Doses of Suspension,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(2):314-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/8383944/pubmed\" target=\"_blank\" id=\"8383944\">8383944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ODoherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. <i>Eur J Clin Microbiol Infect Dis</i>. 1996;15(9):718-724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/8922571/pubmed\" target=\"_blank\" id=\"8922571\">8922571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. <i>J Dermatol</i>. 2001;28(1):1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/11280457/pubmed\" target=\"_blank\" id=\"11280457\">11280457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsey PS, Vaules MB, Vasdev GM, et al, &quot;Maternal and Transplacental Pharmacokinetics of Azithromycin,&quot; <i>Am J Obstet Gynecol</i>, 2003, 188(3):714-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17123995/pubmed\" target=\"_blank\" id=\"17123995\">17123995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. <i>Ann Fam Med</i>. 2014;12(2):121-127. doi: 10.1370/afm.1601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24615307/pubmed\" target=\"_blank\" id=\"24615307\">24615307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. <i>Am J Epidemiol</i>. 1989;129(4):837-849.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/2646920/pubmed\" target=\"_blank\" id=\"2646920\">2646920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Murray KT, Hall K, et al, &quot;Azithromycin and the Risk of Cardiovascular Death,&quot; <i>N Engl J Med</i>. 2012, 366(20):1881-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22591294/pubmed\" target=\"_blank\" id=\"22591294\">22591294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers&rsquo; diarrhea: a graded expert panel report. <i>J Travel Med.</i> 2017;24(suppl 1):S57-S74. doi: 10.1093/jtm/tax026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/28521004/pubmed\" target=\"_blank\" id=\"28521004\">28521004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16760445\"></a>Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. <i>N Engl J Med</i>. 2006;354(23):2452-2462.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/16760445/pubmed\" target=\"_blank\" id=\"16760445\">16760445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaad UB, Kellerhals P, Altwegg M; Swiss Pharyngitis Study Group. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. <i>Pediatr Infect Dis J</i>. 2002;21(4):304-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/12075761/pubmed\" target=\"_blank\" id=\"12075761\">12075761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. <i>Clin Infect Dis.</i> 2017;65(12):e45-e80. doi: 10.1093/cid/cix669.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/29053792/pubmed\" target=\"_blank\" id=\"29053792\">29053792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>, 2014; 58(10):1496]. <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. <i>Am J Obstet Gynecol</i>. 2015;212(6):812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/25595580/pubmed\" target=\"_blank\" id=\"25595580\">25595580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Svanstr&ouml;m H, Pasternak B, and Hviid A, &quot;Use of Azithromycin and Death from Cardiovascular Causes,&quot; <i>N Engl J Med</i>, 2013; 368(18):1704-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/23635050/pubmed\" target=\"_blank\" id=\"23635050\">23635050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27682034\"></a>Tita AT, Szychowski JM, Boggess K, et al. Adjunctive azithromycin prophylaxis for cesarean delivery. <i>N Engl J Med</i>. 2016;375(13):1231-1241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27682034/pubmed\" target=\"_blank\" id=\"27682034\">27682034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trevisani L, Sartori S, Caselli M, Ruina M, Verdianelli G, Abbasciano V. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 1998;93(3):390-393.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/9517646/pubmed\" target=\"_blank\" id=\"9517646\">9517646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17205438\"></a>Tribble DR, Sanders JW, Pang LW, et al. Traveler&rsquo;s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. <i>Clin Inf Dis</i>. 2007;44 (3):338-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17205438/pubmed\" target=\"_blank\" id=\"17205438\">17205438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24746000\"></a>Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Respir Med</i>. 2014;2(5):361-368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/24746000/pubmed\" target=\"_blank\" id=\"24746000\">24746000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22716978\"></a>Vannier E and Krause PJ, &ldquo;Human Babesiosis,&rdquo; <i>N Engl J Med</i>, 2012, 366(25):2397-2407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22716978/pubmed\" target=\"_blank\" id=\"22716978\">22716978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20619683\"></a>Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? <i>J Heart Lung Transplant</i>. 2010;29(12):1358-1368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/20619683/pubmed\" target=\"_blank\" id=\"20619683\">20619683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wahlstrom E, Zamora JU, and Teichman S, &ldquo;Improvement in Cyclosporin-Associated Gingival Hyperplasia With Azithromycin Therapy,&rdquo; <i>N Engl J Med</i>, 1995, 332(11):753-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/7854392/pubmed\" target=\"_blank\" id=\"7854392\">7854392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson R and Wells AU, &ldquo;Azithromycin in Bronchiectasis: When Should it be Used?&rdquo; <i>Lancet</i>, 2012, 380(9842):627-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22901872/pubmed\" target=\"_blank\" id=\"22901872\">22901872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22901887\"></a>Wong C, Jayaram L, Karalus N, et al, &ldquo;Azithromycin for Prevention of Exacerbations in Non-Cystic Fibrosis Bronchiectasis (EMBRACE): A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>Lancet</i>, 2012, 380(9842):660-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/22901887/pubmed\" target=\"_blank\" id=\"22901887\">22901887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1. 2005. Available at http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf?ua=1</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidelines for the Treatment of<i> Chlamydia trachomatis.</i> Geneva, Switzerland: World Health Organization; 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27559553/pubmed\" target=\"_blank\" id=\"27559553\">27559553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidelines for the Treatment of<i> Neisseria gonorrhoeae.</i> Geneva, Switzerland: World Health Organization; 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/27512795/pubmed\" target=\"_blank\" id=\"27512795\">27512795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol</i>. 2016;74(5):945-973.e33. doi: 10.1016/j.jaad.2015.12.037.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azithromycin-systemic-drug-information/abstract-text/26897386/pubmed\" target=\"_blank\" id=\"26897386\">26897386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zithromax IV Infusion (azithromycin) [prescribing information]. New York, NY: Pfizer Labs; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zithromax (azithromycin) 250 mg and 500 mg tablets and oral suspension [prescribing information]. New York, NY: Pfizer Labs; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zithromax (azithromycin) 600 mg tablets and oral suspension [prescribing information]. New York, NY: Pfizer Labs; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zmax (azithromycin) [prescribing information]. New York, NY: Pfizer Labs; January 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8868 Version 281.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7983183\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7983184\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7983188\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7983294\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7983293\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7983295\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7983296\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7983297\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7983340\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7983186\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7983300\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7983211\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475163\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7983163\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7983244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7983221\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7983222\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F7983249\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7983250\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7983254\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7983214\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7983215\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7983220\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F7983299\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7983325\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7983260\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7983262\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7983342\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961955\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8868|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=azithromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Azithromycin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=azithromycin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}